1832 Asset Management L.P. Incyte Corp Transaction History

1832 Asset Management L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$72.82 - $86.52 $54.6 Million - $64.9 Million	-750,400 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$73.52 - $88.7 $33.3 Million - $40.2 Million	453,000 Added 152.32%	750,400 $62.2 Million
Q1 2019 May 15, 2019	BUY	$63.56 - $88.17 $18.9 Million - $26.2 Million	297,400 New	297,400 $24.8 Million
Q1 2018 May 15, 2018	SELL	$83.06 - $100.98 $789,070 - $959,310	-9,500 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$93.56 - $116.6 $518,977 - $646,780	-5,547 Reduced 36.86%	9,500 $896,000
Q3 2017 Nov 14, 2017	BUY	$109.15 - $138.27 $1.64 Million - $2.08 Million	15,047	15,047 $1.7 Million

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.7B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of 1832 Asset Management L.P., based on Form 13F filings with the SEC.

Stay updated on 1832 Asset Management L.P. with notifications on news.